Literature DB >> 22856876

Pulmonary vaccine delivery: a realistic approach?

Wouter F Tonnis1, Gideon F Kersten, Henderik W Frijlink, Wouter L J Hinrichs, Anne H de Boer, Jean-Pierre Amorij.   

Abstract

Pulmonary vaccine delivery has gained increasing attention during the last decade because this vaccination method combines potential advantages such as the fact that it omits the use of needles and may elicit immunity at the port of entry for many pathogens. In this review the current status of pulmonary vaccination, the potential advantages of pulmonary vaccine delivery, the hurdles to overcome in the future, and the overall perspectives of this vaccination strategy are described.

Mesh：

Substances：

Year:  2012        PMID： 22856876     DOI： 10.1089/jamp.2011.0931

Source DB:  PubMed          Journal:  J Aerosol Med Pulm Drug Deliv        ISSN： 1941-2711            Impact factor:   2.849


  13 in total

1.  Biomimetics of the pulmonary environment in vitro: A microfluidics perspective.

Authors:  Janna Tenenbaum-Katan; Arbel Artzy-Schnirman; Rami Fishler; Netanel Korin; Josué Sznitman
Journal:  Biomicrofluidics       Date:  2018-05-29       Impact factor: 2.800

2.  The COPD Pipeline, XXV.

Authors:  Nicholas Gross
Journal:  Chronic Obstr Pulm Dis       Date:  2014-09-25

3.  Engineering of an inhalable DDA/TDB liposomal adjuvant: a quality-by-design approach towards optimization of the spray drying process.

Authors:  Pall Thor Ingvarsson; Mingshi Yang; Helle Mulvad; Hanne Mørck Nielsen; Jukka Rantanen; Camilla Foged
Journal:  Pharm Res       Date:  2013-06-22       Impact factor: 4.200

Review 4.  Inhalable mRNA vaccines for respiratory diseases: a roadmap.

Authors:  Esther H Roh; Catherine A Fromen; Millicent O Sullivan
Journal:  Curr Opin Biotechnol       Date:  2021-12-08       Impact factor: 10.279

5.  Nonpathologic Infection of Macaques by an Attenuated Mycobacterial Vaccine Is Not Reactivated in the Setting of HIV Co-Infection.

Authors:  Taylor W Foreman; Ashley V Veatch; Denae N LoBato; Peter J Didier; Lara A Doyle-Meyers; Kasi E Russell-Lodrigue; Andrew A Lackner; Konstantin G Kousoulas; Shabaana A Khader; Deepak Kaushal; Smriti Mehra
Journal:  Am J Pathol       Date:  2017-09-19       Impact factor: 5.770

Review 6.  Development of cross-protective influenza a vaccines based on cellular responses.

Authors:  Peter Christiaan Soema; Elly van Riet; Gideon Kersten; Jean-Pierre Amorij
Journal:  Front Immunol       Date:  2015-05-15       Impact factor: 7.561

7.  Size-dependent accumulation of particles in lysosomes modulates dendritic cell function through impaired antigen degradation.

Authors:  Emilie Seydoux; Barbara Rothen-Rutishauser; Izabela M Nita; Sandor Balog; Amiq Gazdhar; Philip A Stumbles; Alke Petri-Fink; Fabian Blank; Christophe von Garnier
Journal:  Int J Nanomedicine       Date:  2014-08-13

8.  Adjuvantation of Pulmonary-Administered Influenza Vaccine with GPI-0100 Primarily Stimulates Antibody Production and Memory B Cell Proliferation.

Authors:  Harshad P Patil; José Herrera Rodriguez; Jacqueline de Vries-Idema; Tjarko Meijerhof; Henderik W Frijlink; Wouter L J Hinrichs; Anke Huckriede
Journal:  Vaccines (Basel)       Date:  2017-07-27

9.  Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo.

Authors:  Arwen F Altenburg; Carolien E van de Sandt; Bobby W S Li; Ronan J MacLoughlin; Ron A M Fouchier; Geert van Amerongen; Asisa Volz; Rudi W Hendriks; Rik L de Swart; Gerd Sutter; Guus F Rimmelzwaan; Rory D de Vries
Journal:  Sci Rep       Date:  2017-08-17       Impact factor: 4.379

10.  Nanoparticle surface charge impacts distribution, uptake and lymph node trafficking by pulmonary antigen-presenting cells.

Authors:  Catherine A Fromen; Tojan B Rahhal; Gregory R Robbins; Marc P Kai; Tammy W Shen; J Christopher Luft; Joseph M DeSimone
Journal:  Nanomedicine       Date:  2015-12-01       Impact factor: 5.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.